The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

(2019) Dilan Athauda et al.   JAMA Neurology

The Cardiometabolic Risk Profile of Young Adults With Diabetes in the U.S.

(2019) Sharon H. Saydah et al.   DIABETES CARE

Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes

(2019) Eman A. Elbassuoni et al.   NEUROCHEMISTRY INTERNATIONAL

Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies

(2018) Ivan Martinez-Valbuena et al.   ACTA NEUROPATHOLOGICA

Striatal synapses, circuits, and Parkinson's disease

(2018) Shenyu Zhai et al.   CURRENT OPINION IN NEUROBIOLOGY

Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats

(2018) Yu-Wen Yu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of View

(2018) Alice Biosa et al.   MOLECULAR NEUROBIOLOGY

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

(2018) Seung Pil Yun et al.   NATURE MEDICINE

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

(2018) Steven E. Arnold et al.   Nature Reviews Neurology

Diabetes mellitus and Parkinson disease

(2018) Gennaro Pagano et al.   NEUROLOGY

Association between diabetes and subsequent Parkinson disease

(2018) Eduardo De Pablo-Fernandez et al.   NEUROLOGY

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

(2018) Dilan Athauda et al.   NEUROPHARMACOLOGY

Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?

(2018) Ana Marques et al.   PARKINSONISM & RELATED DISORDERS

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease

(2018) Annekatrin König et al.   Journal of Parkinsons Disease

Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease

(2018) Seok Jong Chung et al.   PARKINSONISM & RELATED DISORDERS

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) E. Ray Dorsey et al.   LANCET NEUROLOGY

Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus

(2018) Norlinah Mohamed Ibrahim et al.   MOVEMENT DISORDERS

Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson’s Disease and Diabetes as Well as Potential Therapies?

(2018) Guadalupe Vidal-Martinez et al.   Frontiers in Molecular Neuroscience

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease

(2017) Ziyue Yuan et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

(2017) Ramón Cacabelos   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Epidemiology of Parkinson’s disease

(2017) Ole-Bjørn Tysnes et al.   JOURNAL OF NEURAL TRANSMISSION

Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain

(2017) Kymry T. Jones et al.   JOURNAL OF NEUROCHEMISTRY

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Increased risk of Parkinson disease with diabetes mellitus in a population-based study

(2017) Yu-Wan Yang et al.   MEDICINE

Glitazone use associated with reduced risk of Parkinson's disease

(2017) Brage Brakedal et al.   MOVEMENT DISORDERS

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

(2017) Yan Zheng et al.   Nature Reviews Endocrinology

Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease

(2016) M. Petrou et al.   ACADEMIC RADIOLOGY

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF

(2016) Chenhui Ji et al.   BRAIN RESEARCH

Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes

(2016) Caterina Palleria et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson’s Disease via Autophagy and Mitochondrial ROS Clearance

(2016) Ming Lu et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Risk of Parkinson Disease in Diabetes Mellitus

(2016) Xuejing Yue et al.   MEDICINE

Glycation in Parkinson's disease and Alzheimer's disease

(2016) Hugo Vicente Miranda et al.   MOVEMENT DISORDERS

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model

(2016) Yanwei Li et al.   NEUROPHARMACOLOGY

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain

(2016) Lijun Cao et al.   NEUROREPORT

Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease

(2016) Istvan Horvath et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin resistance and Parkinson’s disease: A new target for disease modification?

(2016) D. Athauda et al.   PROGRESS IN NEUROBIOLOGY

Thiazolidinediones and Parkinson Disease: A Cohort Study

(2015) John G. Connolly et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity

(2015) Claudia A. Grillo et al.   DIABETES

Eating High Fat Chow Decreases Dopamine Clearance in Adolescent and Adult Male Rats but Selectively Enhances the Locomotor Stimulating Effects of Cocaine in Adolescents

(2015) M. G. Baladi et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

Type 2 diabetes mellitus and biomarkers of neurodegeneration

(2015) Chris Moran et al.   NEUROLOGY

Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice

(2015) R. Khang et al.   NEUROSCIENCE

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

Insulin resistance in brain alters dopamine turnover and causes behavioral disorders

(2015) Andre Kleinridders et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward

(2015) Melissa A. Stouffer et al.   Nature Communications

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

(2015) Iciar Aviles-Olmos et al.   Journal of Parkinsons Disease

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

(2015) Ruth Brauer et al.   PLOS MEDICINE

First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease

(2014) Christian Hölscher   Alzheimers & Dementia

The Ability of Insulin To Inhibit the Formation of Amyloid by Pro-Islet Amyloid Polypeptide Processing Intermediates Is Significantly Reduced in the Presence of Sulfated Glycosaminoglycans

(2014) Hui Wang et al.   BIOCHEMISTRY

GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats

(2014) Ajaykumar N. Sharma et al.   METABOLIC BRAIN DISEASE

Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates

(2014) Christine Swanson et al.   NEUROLOGICAL RESEARCH

Insulin resistance and gray matter volume in neurodegenerative disease

(2014) J.K. Morris et al.   NEUROSCIENCE

Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study

(2014) Martina Giuntini et al.   PARKINSONISM & RELATED DISORDERS

Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease

(2014) Nicolaas I. Bohnen et al.   PARKINSONISM & RELATED DISORDERS

Diabetes and Risk of Parkinson's Disease: An Updated Meta-Analysis of Case-Control Studies

(2014) Lin Lu et al.   PLoS One

Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain

(2014) Zhihong Chen et al.   Nature Communications

Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study

(2014) Edward W Gregg et al.   Lancet Diabetes & Endocrinology

Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice

(2013) Ling Wang et al.   EXPERIMENTAL NEUROLOGY

Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology

(2013) Venus Thomanetz et al.   JOURNAL OF CELL BIOLOGY

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Peripheral expression of MAPK pathways in Alzheimer’s and Parkinson’s diseases

(2013) Shan Wang et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress

(2013) Mohit K. Sharma et al.   JOURNAL OF NEUROCHEMISTRY

Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease

(2013) Laura Dunn et al.   NEUROBIOLOGY OF AGING

Diabetes is associated with postural instability and gait difficulty in Parkinson disease

(2013) Vikas Kotagal et al.   PARKINSONISM & RELATED DISORDERS

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Shared dysregulated pathways lead to Parkinson's disease and diabetes

(2013) Jose A. Santiago et al.   TRENDS IN MOLECULAR MEDICINE

Meta-analysis of early nonmotor features and risk factors for Parkinson disease

(2012) Alastair J. Noyce et al.   ANNALS OF NEUROLOGY

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Parkinson's disease, insulin resistance and novel agents of neuroprotection

(2012) Iciar Aviles-Olmos et al.   BRAIN

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat

(2012) Amjad Abuirmeileh et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Dementia is associated with Insulin Resistance in patients with Parkinson's Disease

(2012) Domenico Bosco et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Clinical features of Parkinson disease when onset of diabetes came first: A case-control study

(2012) E. Cereda et al.   NEUROLOGY

The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease

(2012) Caitriona M. Long-Smith et al.   NEUROMOLECULAR MEDICINE

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

Diabetes and Risk of Parkinson's Disease: A systematic review and meta-analysis

(2011) E. Cereda et al.   DIABETES CARE

Diabetes and the Risk of Developing Parkinson's Disease in Denmark

(2011) E. Schernhammer et al.   DIABETES CARE

Diabetes and Risk of Parkinson's Disease

(2011) Q. Xu et al.   DIABETES CARE

Subsecond regulation of striatal dopamine release by pre-synaptic KATP channels

(2011) Jyoti C. Patel et al.   JOURNAL OF NEUROCHEMISTRY

Obesity, diabetes, and risk of Parkinson's disease

(2011) Natalia Palacios et al.   MOVEMENT DISORDERS

Subsequent Risks of Parkinson Disease in Patients with Autoimmune and Related Disorders: A Nationwide Epidemiological Study from Sweden

(2011) Xinjun Li et al.   Neurodegenerative Diseases

Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis

(2010) R. Fan et al.   DIABETES OBESITY & METABOLISM

Epidemiology of Type 1 Diabetes

(2010) David M. Maahs et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

(2010) Jonathan Wills et al.   EXPERIMENTAL NEUROLOGY

Synaptic plasticity, dopamine and Parkinson's disease: one step ahead

(2009) P. Calabresi et al.   BRAIN

The Irs1 Branch of the Insulin Signaling Cascade Plays a Dominant Role in Hepatic Nutrient Homeostasis

(2009) S. Guo et al.   MOLECULAR AND CELLULAR BIOLOGY

Autoimmune disease and risk for Parkinson disease: A population-based case-control study

(2009) K. Rugbjerg et al.   NEUROLOGY

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

[11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

(2009) A.L. Bartels et al.   PARKINSONISM & RELATED DISORDERS

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inactivation of Hepatic Foxo1 by Insulin Signaling Is Required for Adaptive Nutrient Homeostasis and Endocrine Growth Regulation

(2008) Xiaocheng C. Dong et al.   Cell Metabolism

Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease

(2008) J. A. Driver et al.   DIABETES CARE

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

(2008) Anthony HV Schapira   LANCET NEUROLOGY

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH